Literature DB >> 25693844

MBL2 polymorphisms in women with atypical squamous cells of undetermined significance.

Luisa Zupin1, Vania Polesello, Giorgia Casalicchio, Nadia Freato, Iva Maestri, Manola Comar, Sergio Crovella, Ludovica Segat.   

Abstract

Infection with high risk Human papillomavirus (HPV) is the main known cause of cervical cancer. HPV induces different grades of lesions: among them, Atypical squamous cells of undetermined significance are abnormal lesions that could evolve in pre-cancer lesions or spontaneously regress. The mannose binding lectin (MBL) is an innate immunity serum protein also found in cervico-vaginal mucosa, whose expression is known to be affected by polymorphisms in exon 1 and promoter of the MBL2 gene. In the present study the possible association between MBL2 functional polymorphisms and susceptibility to develop atypical squamous cells of undetermined significance was investigated in a group of women from North-East of Italy, stratified for HPV infection status. The MBL2 D and O alleles and the deficient producer combined genotypes, responsible for low MBL production, were more represented among atypical squamous cells of undetermined significance positive women than healthy controls and the results were confirmed when only HPV negative samples were considered. These results suggest a possible involvement of MBL2 functional polymorphisms in atypical squamous cells of undetermined significance susceptibility.
© 2015 Wiley Periodicals, Inc.

Entities:  

Keywords:  HPV infection; MBL; SNPs; innate immunity

Mesh:

Substances:

Year:  2015        PMID: 25693844     DOI: 10.1002/jmv.24080

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  1 in total

1.  Mannose-Binding Lectin Does Not Act as a Biomarker for the Progression of Preinvasive Lesions of Invasive Cervical Cancer.

Authors:  Carlos Afonso Maestri; Renato Nisihara; Guilherme P Ramos; Hellen Weinschutz Mendes; Iara Messias-Reason; Newton Sérgio de Carvalho
Journal:  Med Princ Pract       Date:  2017-11-07       Impact factor: 1.927

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.